Novartis AG ADR
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $13,172,000 | $12,512,000 | $11,829,000 | $11,776,000 |
Gross Profit | 9,938,000 | 9,295,000 | 8,699,000 | 8,754,000 |
EBITDA | 5,618,000 | 5,251,000 | 4,693,000 | 4,206,000 |
EBIT | 3,653,000 | 4,089,000 | 3,379,000 | 2,618,000 |
Net Income | 3,189,000 | 3,246,000 | 2,688,000 | 8,480,000 |
Net Change In Cash | 13,172,000 | 12,512,000 | 11,829,000 | 11,776,000 |
Free Cash Flow | 5,487,000 | 4,147,000 | 1,109,000 | 1,764,000 |
Cash | 13,609,000 | 7,903,000 | 9,469,000 | 13,393,000 |
Basic Shares | 2,027,000 | 2,046,000 | 2,056,000 | 2,065,000 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $46,660,000 | $51,828,000 | $52,877,000 | $49,898,000 |
Gross Profit | 34,188,000 | 36,342,000 | 37,010,000 | 34,777,000 |
EBITDA | 18,286,000 | 14,726,000 | 17,132,000 | 15,236,000 |
EBIT | 10,009,000 | 8,021,000 | 11,703,000 | 10,126,000 |
Net Income | 14,850,000 | 6,955,000 | 24,021,000 | 8,072,000 |
Net Change In Cash | 46,660,000 | 51,828,000 | 52,877,000 | 49,898,000 |
Free Cash Flow | 11,705,000 | 11,565,000 | 12,100,000 | 11,065,000 |
Cash | 13,393,000 | 7,517,000 | 12,407,000 | 9,658,000 |
Basic Shares | 2,092,000 | 2,197,000 | 2,260,000 | 2,296,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $2.06 |
2024-06-30 | $1.97 |
2024-03-31 | $1.80 |
2023-12-31 | $1.53 |
